Related Experiment Videos
beta2-microglobulin-derived amyloidosis: an update
1Division of Nephrology, University of Aachen, Aachen, Germany. juergen.Floege@post.rwth-aachen.de
Abstract:
The present review attempts to summarize recent developments in the field of beta2-microglobulin-derived amyloidosis (A(beta2)m amyloidosis) in patients on chronic dialysis therapy. A key factor in the pathogenesis is the uremic retention of the precursor molecule, beta2-microglobulin (beta2m). However, secondary modifications of the molecule such as limited proteolysis, conformational changes, and the formation of advanced glycation end products have also been described. Finally, in order to explain the striking predilection of the disease for synovial and periarticular structures, a role of local predisposing factors within the synovial membrane (for example, of the particular constituents of the extracellular matrix) must also be postulated. With respect to clinical symptomatology, recent data have confirmed that clinically manifest signs of the amyloidosis represent only the tip of the iceberg, since histologically amyloid deposition is much more widespread. Noninvasive diagnosing of the disease has been advanced by technical changes of the beta2m scintigraphy. Finally, there is accumulating evidence that prevention of the disease not only includes the usage of high-flux synthetic membranes for hemodialysis or hemodiafiltration, but that other factors contribute to the clinical manifestations of amyloidosis such as the dialysate composition and its microbacteriological quality. Such factors, which have changed over the last years as part of general improvements in dialysis care, may explain why the prevalence of the amyloidosis appears to decrease.
Insights
Beta2-microglobulin-derived amyloidosis (Aβ2m amyloidosis) in dialysis patients stems from retained beta2-microglobulin (β2m). Recent advancements focus on prevention strategies and improved diagnostics for this condition.
Area of Science:
- Nephrology
- Biochemistry
- Pathology
Background:
- Beta2-microglobulin (β2m) accumulation in chronic kidney disease patients undergoing dialysis is a key factor in Aβ2m amyloidosis.
- Secondary molecular modifications, including proteolysis and glycation, contribute to β2m amyloid formation.
- Local factors in synovial membranes may predispose to amyloid deposition in joints.
Purpose of the Study:
- To review recent developments in beta2-microglobulin-derived amyloidosis (Aβ2m amyloidosis) in patients on chronic dialysis.
- To summarize advances in understanding pathogenesis, diagnosis, and prevention of Aβ2m amyloidosis.
Main Methods:
- Review of recent literature on Aβ2m amyloidosis.
- Analysis of factors contributing to disease pathogenesis, clinical presentation, and diagnosis.
- Evaluation of preventive strategies in dialysis therapy.
Main Results:
- Clinically apparent Aβ2m amyloidosis is less widespread than histological findings suggest.
- Technical improvements in β2m scintigraphy enhance noninvasive diagnosis.
- High-flux dialysis membranes, dialysate quality, and composition are crucial for Aβ2m amyloidosis prevention.
Conclusions:
- Aβ2m amyloidosis pathogenesis involves β2m retention, molecular modifications, and local factors.
- Early diagnosis and prevention strategies are critical for managing Aβ2m amyloidosis in dialysis patients.
- Improvements in dialysis technology and care may be reducing the prevalence of Aβ2m amyloidosis.